araag2/HINT huggingface dataset:
Clinical trial NCT00319319 (phase 2, status: completed)
Conditions: depressive disorder
ICD codes: F25.1, F33.0, F33.1, F33.9, F32.0, F32.1, F32.9
Drugs: mecamylamine hydrochloride (inversine)
SMILES: CNC1(C)C2CCC(C2)C1(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Major depression, recurrent outpatients, ages 18-65, smoker or non-smoker, on SSRI
             monotherapy, depression scores on HDRS-17 item scale or = 12.

        Exclusion Criteria:

          -  suicidal or homicidal ideation, need for inpatient or partial hospital care, systolic
             blood pressure <100 mm Hg, history of hypersensitivity to mecamylamine or its
             excipients.
Clinical trial NCT00647192 (phase 2, status: terminated)
Conditions: atrial fibrillation
ICD codes: I48.0, I48.21, I48.91, I48.11, I48.19, I48.20
Drugs: eplerenone, placebo
SMILES: [H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)C[C@H]1O[C@@]11[C@@]2([H])[C@@H](CC2=CC(=O)CC[C@]12C)C(=O)OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    inclusion rate too low. recruitment of further study centers too costly.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Persistent atrial fibrillation (AF), AF persistence for > 7 days but < 1 year

          -  Total AF history < 2 years

          -  Written informed consent of the patient

          -  Age ≥18 years

          -  Female patients are sterilised or postmenopausal or apply an adequate method for
             contraception (Pearl index <1%) and have a negative pregnancy test (ß-HCG) and do not
             breastfeed/nurse.

        Exclusion Criteria:

          -  Hemodynamic instability or symptoms not allowing cardioversion to be delayed for 3
             weeks

          -  Myocardial infarction within the last 3 months

          -  Heart failure NYHA class III - IV

          -  Uncontrolled hypertension, defined as a systolic blood pressure > 160 mm Hg and/or a
             diastolic blood pressure > 95 mm Hg (anti-hypertensive treatment is allowed).

          -  Pre-treatment with an aldosterone antagonist or other potassium sparing diuretics

          -  Instable angina pectoris

          -  Use of Digitalis

          -  Use of class I or class III antiarrhythmic drugs (must be stopped at least 5 half-life
             before)

          -  Contraindication or hypersensitivity to ß-blockers

          -  Open heart surgery within the last 3 months

          -  Pregnancy

          -  Acute and reversible illnesses

          -  Acute and chronic infection

          -  Alcohol or drug abuse or a severe progressive extracardiac disease

          -  Untreated manifest and latent hyper- or hypothyroidism or < 3 months peripheral
             euthyroidism (normal fT3)

          -  Moderate to severe renal insufficiency (Creatinine clearance less than 50 ml/min)

          -  Patients with liver cirrhosis (Child-Pugh class C)

          -  Co-administration of strong CYP3A4 inhibitors (e.g. Itraconazole, Ketoconazole,
             Ritonavir, Nelfinavir, Clarithromycin, Telithromycin and Nephazodon)

          -  Hypersensitivity against Eplerenone and/or one of the other components of the tablet
             (see Fachinformation)

          -  Serum potassium > 5 mmol/l

          -  Patients unlikely to comply with the protocol
Clinical trial NCT01476202 (phase 2, status: completed)
Conditions: smoking cessation
ICD codes: Y36.881S, Y36.891S, Y36.880S, Y36.881A, Y36.881D, Y36.890S, Y36.891A
Drugs: nicotine
SMILES: CC(=O)NC1=CC=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Smoking Status: Current cigarette smokers who have smoked regularly for at least a
             year and smoke their first cigarette more than 30 minutes after waking up.

        Exclusion Criteria:

          -  Allergy/Intolerance: Known or suspected intolerance or hypersensitivity to nicotine
             (or closely related compounds) or any of the stated ingredients in formulation.

          -  Prior Concomitant Medication: a. Treatment with known enzyme altering agents (e.g.
             carbamazepine, phenytoin, cimetidine, sodium valporate) within 30 days of the craving
             provocation visit. b. Use of any prescription psychoactive medication (such as but not
             limited to antidepressants, antipsychotics, anxiolytics) within 14 days of the craving
             provocation visit. c. Use of any over-the-counter (OTC) medication that affects
             central nervous system such as antihistamines, sedating agents, or any compound that
             would have a sedating effect within 24 hours of the craving provocation visit. d. Use
             of any nicotine replacement therapy or any other treatment for smoking cessation (e.g.
             bupropion or varenicline) within one month of screening visit. e. Use of any nicotine
             containing products at any time during the Provocation/Treatment visit. f. Use of any
             medications noted in the exclusion criteria, or use of any product that would, in the
             opinion of the investigator, jeopardize the safety of the subject or impact on the
             validity of the study results.

          -  Any disease that, in the opinion of the investigator, may interfere with the
             absorption, metabolism or excretion of the study product. A medical history that, in
             the opinion of the investigator, might jeopardise the safety of the subject or the
             validity of the study results. For example, recent myocardial infarction or
             cerebrovascular accident (within 12 weeks of the screening visit), phenylketonuria,
             unstable or worsening angina pectoris, Prinzmetals angina or severe cardiac
             arrhythmia.

          -  Expired Carbon Monoxide (CO): Any subject whose CO level rises during the
             sequestration period (i.e., the subject's expired CO assessments immediately prior to
             the provoked craving paradigm are higher than the mean baseline CO assessment) and, in
             the opinion of the investigator, may have smoked during that time.

          -  Alcohol: Consumption of any alcoholic beverage within 24 hours of the craving
             provocation visit, as indicated by a positive breath alcohol test.
Clinical trial NCT00592475 (phase 2, status: completed)
Conditions: liver cirrhosis
ICD codes: K74.60, K74.69, P78.81, K71.7, K70.30, K70.31
Drugs: conivaptan, placebo
SMILES: CC1=NC2=C(CCN(C(=O)C3=CC=C(NC(=O)C4=CC=CC=C4C4=CC=CC=C4)C=C3)C3=CC=CC=C23)N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written
             Informed Consent and appropriate privacy language as per national regulations must be
             obtained from the subject or legally authorized representative prior to any
             study-related procedures (including withdrawal of prohibited medication, if
             applicable)

          -  Subject is euvolemic or hypervolemic (edematous) secondary to cirrhosis

          -  Subject has clinical evidence of portal hypertension by the presence of esophageal
             varices, ascites or both

        Exclusion Criteria:

          -  Clinical evidence of volume depletion or dehydration

          -  Subject has a history of bleeding from esophageal varices within three months before
             the start of the study
Clinical trial NCT00202592 (phase 2, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: perindopril
SMILES: [H][C@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Hypertensive children, who have been treated for four months at least with S90652,
             with safety and efficacy

        Exclusion Criteria:

          -  Poorly controlled hypertension

          -  Girls with signs of pubescence
Clinical trial NCT01263509 (phase 2/phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: alogliptin and voglibose, alogliptin and voglibose
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Had completed the phase 2 dose-ranging study (i.e., the subject had completed the
             study visit at Week 12).

        Exclusion Criteria:

          -  Had clinical manifestations of hepatic impairment (e.g., an aspartate aminotransferase
             or alanine aminotransferase value 2.5 times or more of the upper reference limit at
             Week 8 of treatment in the phase 2 dose-ranging study).

          -  Had clinical manifestations of renal impairment (e.g., a creatinine value of 2 mg/dL
             or more at Week 8 of treatment in the phase 2 dose-ranging study).
Clinical trial NCT01486849 (phase 2, status: completed)
Conditions: amyotrophic lateral sclerosis
ICD codes: G12.21
Drugs: ck-2017357, placebo, riluzole 50 mg
SMILES: CCC(CC)N1C(=O)NC2=NC=C(N=C12)C#C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2
Eligibility criteria:

        Inclusion Criteria:

          1. Able to comprehend and willing to sign an Informed Consent Form (ICF)

          2. Males or females 18 years of age or older

          3. A diagnosis of familial or sporadic ALS (defined as meeting the possible,
             laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS
             according to the World Federation of Neurology El Escorial criteria)

          4. Maximum voluntary grip strength in at least one hand between 10 & 40 pounds (females)
             and 10 & 60 pounds (males)

          5. Able to swallow tablets with water

          6. Currently taking and tolerating a stable dose of 50 mg BID riluzole

          7. Willing and able to reduce daily dose of riluzole to 50mg QD for 5 weeks

          8. Not currently taking or willing and able to remain off theophylline-containing
             medications during study participation

          9. Patient has a caregiver who is capable of observing and reporting patient status

         10. Upright Slow Vital Capacity (SVC) >50% of predicted for age, height, and sex

         11. Able to perform pulmonary function tests

        Exclusion Criteria:

          1. Life expectancy <3 months

          2. Receipt of investigational study drug within 30 days or 5 half-lives of the prior
             agent, whichever is greater, prior to dosing

          3. Any prior treatment with CK-2017357

          4. Any use of non-invasive positive pressure ventilation (NIPPV), such as Continuous
             Positive Airway Pressure (CPAP) or Bilevel Positive Airway Pressure (BiPAP)

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT01118949 (phase 2, status: completed)
Conditions: epilepsy
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801
Drugs: lacosamide
SMILES: COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subject has a diagnosis of uncontrolled epilepsy with primary generalized tonic-clonic
             (PGTC) seizures and idiopathic generalized epilepsy. Diagnosis should have been
             established by an electroencephalogram (EEG) with generalized spike-wave discharges
             within 5 years of the screening visit

          -  Subject has ≥1 PGTC seizure within the 12 weeks prior to the screening visit

          -  Subject has a stable dose regimen of 1 to 3 marketed antiepileptic drug(s) (AEDs) with
             or without additional concurrent stable Vagus Nerve Stimulation (VNS). The VNS must
             have been in place for at least 6 months prior to study entry with constant settings
             for at least 28 days prior to the screening visit and during the Baseline Phase.
             Benzodiazepines will be counted as an AED

        Exclusion Criteria:

          -  Subject has a history of partial-onset seizures or EEG findings consistent with
             partial onset seizures

          -  Subject has a history of status epilepticus within the 5-year Period prior to Visit 1

          -  Subject has a current or previous diagnosis of pseudoseizures, conversion disorders,
             or other non-epileptic ictal events

          -  Subject has any medical or psychiatric condition

          -  Subject has any history of alcohol or drug abuse

          -  Subject is currently taking felbamate

          -  Subject has ever taken vigabatrin and has no visual fields examination report
             available or if results of the examination are abnormal

          -  Subject is on a ketogenic diet

          -  Subject has a known sodium channelopathy
Clinical trial NCT00232206 (phase 2, status: terminated)
Conditions: non-small-cell lung carcinoma
ICD codes: D02.20, D02.21, D02.22
Drugs: neoadjuvant therapy with cisplatin plus docetaxel
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Reason stopped: 
    study terminated due to slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed NSCLC appropriate for surgery

          -  Medically fit for resection by lobectomy or pneumonectomy

          -  T1-2N1 disease by CT must have negative N2/N3 nodes by PET

          -  T3N1 disease must have pathologically negative N2/N3 nodes

          -  Measurable disease

          -  Patients must not be receiving other investigational therapy

          -  Prior surgery for NSCLC okay if resected > or = 5 years prior

          -  No prior chemotherapy or radiation for NSCLC

          -  No uncontrolled medical problems

          -  No factors that would preclude obtaining informed consent

          -  Age 18 or greater

          -  Performance status (PS) 0-1

          -  Peripheral neuropathy must be < grade 1

          -  Acceptable hematologic and chemistry parameters

          -  Renal: creatinine clearance (calculated) > 50 cc/min

        Exclusion Criteria:

          -  History of severe hypersensitivity to docetaxel or like drugs

          -  Pregnant or nursing women

          -  Prior chemotherapy or radiation for NSCLC

          -  Symptomatic superior sulcus tumors

          -  Prior malignancy except for treated non-melanoma skin cancer, in situ cervical cancer,
             localized prostate cancer or cancer from which the patient has been disease free for
             greater than three years
Clinical trial NCT00687271 (phase 2, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: mk-6213, atorvastatin calcium, placebo for mk-6312 160 mg, placebo for atorvastatin 20 mg
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  18 to 75 years of age at the time of the study with high cholesterol

          -  Can have diabetes mellitus but is not currently on lipid lowering therapy

          -  Have a stable weight for >6 weeks

        Exclusion Criteria:

          -  Has significant cardiovascular (heart), renal (kidney), neurologic (nervous system),
             respiratory (lung), hepatic (liver) or metabolic disease

          -  history of mental instability or drug/alcohol abuse within the past 5 years

          -  Pregnant or nursing; human immunodeficiency virus (HIV) positive; history of cancer
             within the past 5 years or participation in an investigational trial within the last
             30 days
Clinical trial NCT01157377 (phase 2, status: completed)
Conditions: urinary bladder, overactive
ICD codes: N32.81
Drugs: agn-214868, agn-214868 placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  If female, must be of nonreproductive potential

          -  If male, must agree to use acceptable contraception

          -  Symptoms of overactive bladder with urinary urgency incontinence

          -  Inadequate response or limiting side effects with anticholinergics for the treatment
             of OAB

        Exclusion Criteria:

          -  Overactive bladder caused by neurological condition (eg, spinal cord injury, multiple
             sclerosis)

          -  History of bladder surgery

          -  Treatment with botulinum toxin therapy of any serotype for any non-urological
             condition within the prior 12 weeks

          -  Previous treatment with botulinum toxin therapy of any serotype for any urological
             condition
Clinical trial NCT01501604 (phase 2, status: withdrawn)
Conditions: lung cancer, breast cancer, colorectal cancer, cholangiocarcinoma, solid tumors
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: bkm120
SMILES: FC(F)(F)C1=CC(=N)NC=C1C1=CC(=NC(=N1)N1CCOCC1)N1CCOCC1
Reason stopped: 
    the study has been closed due to lack of accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  At least 1 site of measurable disease

          -  Life expectancy >/= 12 weeks

          -  Adequate marrow and organ function

          -  Diagnosis of lung cancer, breast cancer, colorectal cancer, cholangiocarcinoma,
             gastric cancer, pancreatic cancer, prostate cancer, uterine cancer, ovarian cancer,
             esophageal cancer, or head and neck cancer

          -  Pathologically documented, definitively diagnosed, advanced solid tuor that is
             refractory to standard treatment, for which no standard therapy is available, or the
             subject refuses standard therapy

          -  Cancer must have at least one of the following PIK3CA mutations: E542K, E545K, H1047R,
             H1047L. The PIK3CA mutation must be documented in a CLIA approved laboratory

        Exclusion Criteria:

          -  Prior treatment with a P13K inhibitor

          -  Known hypersensitivity to BKM120 or its excipients

          -  Untreated brain metastases

          -  Acute or chronic liver, renal disease or pancreatitis

          -  Currently treated with drugs known to be moderate and strong inhibitors or inducers of
             isoenzyme CYP3A

          -  Diarrhea >/= CTCAE grade 2

          -  Any concurrent severe and/or uncontrolled medical condition

          -  Active cardiac disease

          -  History of cardiac dysfunction

          -  Poorly controlled diabetes mellitus or steroid-induced diabetes mellitus

          -  Significant symptomatic deterioration of lung function

          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly
             alter the absorption of BKDM120 (e.g., ulcerative diseases, uncontrolled nausea,
             vomiting, diarrhea, malabsorption syndrome, or small bowel resection)

          -  Currently taking therapeutic doses of warfarin sodium or any other coumadin-derivative
             anticoagulant

          -  Pregnant or breast-feeding

          -  Known diagnosis of HIV infection

          -  History of another malignancy within 3 years, except cured basal cell carcinoma of the
             skin or excised carcinoma in situ of the cervix

          -  Unable to swallow the medication in its prescribed form
Clinical trial NCT00208949 (phase 2, status: terminated)
Conditions: hematologic diseases
ICD codes: E70.338, E70.339, P09.3, O28.0, P61.8, P61.9, T45.8X1A
Drugs: g-csf, gm-csf
SMILES: C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  All normal donors for patients undergoing allogeneic peripheral blood stem cell (PBSC)
             for hematologic diseases will be invited to participate in this research trial.

          -  All patients must meet criteria for transplantation.

          -  Final eligibility will be determined by the health professionals conducting this
             clinical trial.

        Exclusion Criteria:

          -  Donors for patients undergoing selected or manipulated PBSC grafts are not eligible.

          -  Donors who are pregnant or lactating females and donors with a known hypersensitivity
             to either G-CSF or GM-CSF will be excluded from this study.

          -  Final eligibility will be determined by the health professionals conducting this
             clinical trial.
Clinical trial NCT00625352 (phase 2, status: unknown status)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: gemcitabine, uft
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically- or cytologically- confirmed Non-Small-Cell Lung Cancer Stage IIIB/IV

          -  No prior chemotherapy

          -  Existence of measurable disease. The measurable disease should not have been
             irradiated

          -  Life expectancy of more than 3 months

          -  Age ≥ 70 years

          -  Performance status (ECOG):1 or 2

          -  Adequate bone marrow function (Absolute neutrophil count >1500/mm^3, Platelet
             count>100000/mm^3, Hemoglobin>9gr/mm^3)

          -  Adequate liver (Bilirubin<2 times upper limit of normal and SGOT/SGPT<3 times upper
             limit of normal) and renal function (creatinine<1.5mg/dl)

          -  Informed consent

        Exclusion Criteria:

          -  Psychiatric illness or social situation that would preclude study compliance.

          -  Other concurrent uncontrolled illness.

          -  Other invasive malignancy within the past 5 years except nonmelanoma skin cancer

          -  Currently/recently taken warfarin, phenprocoumon or phenytoin

          -  Hypersensitivity history to any drug